H. Development of non-invasive systems for monitoring the total hemoglobin and hematocrit, suitable for use with adults or neonates. I. Application of nanotechnology to the measurement of parameters and diagnosis of blood disorders. J. Development of new methods for the non-invasive or minimally invasive measurement of body iron. K. Adaptation of MRI technology for the non-invasive measurement of body iron: 1. Develop appropriate MR measurement method(s). 2. Optimize RF coils for the body region of interest (primarily heart, liver, and pancreas). 3. Develop magnets of the appropriate magnetic field strength(s). 4. Develop a reliable method for calibrating, validating, and standardizing organ specific iron concentration measurements as detected by magnetic resonance imaging. 5. Determine the most appropriate magnetic resonance method for determining relaxation and susceptibility. 6. Develop indicator materials for direct MR measurement of iron concentration. L. Design of therapeutic drugs for inducing fetal hemoglobin synthesis. M. Development and validation of a sensitive, specific, reproducible, quantitative, and clinically applicable assay method for measuring serum hepcidin levels, as well as cellular hepcidin and ferroportin expression levels. N. Design and validation of novel therapeutic agents that modulate hepcidin and cellular ferroportin expression and/or activity in vivo. Other Research Topic(s) Within the Mission of the Institute For additional information on research topics, contact: Dr. Guillermo Arreaza-Rubín National Institute of Diabetes and Digestive and Kidney Diseases 301-594-4724 Email: Ms. Christine Densmore National Institute of Diabetes and Digestive and Kidney Diseases 301-402-8714 Email: Kidney Dr. Marva Moxey-Mims National Institute of Diabetes and Digestive and Kidney Diseases 301-594-7717 Email:
H. Development of non-invasive systems for monitoring the total hemoglobin and hematocrit, suitable for use with adults or neonates. I. Application of nanotechnology to the measurement of parameters and diagnosis of blood disorders. J. Development of new methods for the non-invasive or minimally invasive measurement of body iron. K. Adaptation of MRI technology for the non-invasive measurement of body iron: 1. Develop appropriate MR measurement method(s). 2. Optimize RF coils for the body region of interest (primarily heart, liver, and pancreas). 3. Develop magnets of the appropriate magnetic field strength(s). 4. Develop a reliable method for calibrating, validating, and standardizing organ specific iron concentration measurements as detected by magnetic resonance imaging. 5. Determine the most appropriate magnetic resonance method for determining relaxation and susceptibility. 6. Develop indicator materials for direct MR measurement of iron concentration. L. Design of therapeutic drugs for inducing fetal hemoglobin synthesis. M. Development and validation of a sensitive, specific, reproducible, quantitative, and clinically applicable assay method for measuring serum hepcidin levels, as well as cellular hepcidin and ferroportin expression levels. N. Design and validation of novel therapeutic agents that modulate hepcidin and cellular ferroportin expression and/or activity in vivo. Other Research Topic(s) Within the Mission of the Institute For additional information on research topics, contact: Dr. Guillermo Arreaza-Rubín National Institute of Diabetes and Digestive and Kidney Diseases 301-594-4724 Email: Ms. Christine Densmore National Institute of Diabetes and Digestive and Kidney Diseases 301-402-8714 Email: Kidney Dr. Marva Moxey-Mims National Institute of Diabetes and Digestive and Kidney Diseases 301-594-7717 Email:
2015-2_SBIR-STTR-Topics.docx